A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications
- PMID: 29205637
- DOI: 10.1002/gcc.22517
A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications
Abstract
Recently, many genome-wide profiling studies provided insights into the molecular make-up of major cancer types. The deeper understanding of these genetic alterations and their functional consequences led to the discovery of novel therapeutic opportunities improving clinical management of cancer patients. While tissue-based molecular patient stratification is the gold standard for precision medicine, it has certain limitations: Tissue biopsies are invasive sampling procedures carrying the risk of complications and may not represent the entire tumor due to underlying genetic heterogeneity. In this context, complementary characterization of genetic information in the blood of cancer patients can serve as minimal-invasive 'liquid biopsy'. Fragments of circulating cell-free DNA (cfDNA) are released from tissues of healthy individuals as well as cancer patients. The fraction of cfDNA that is released from primary tumors or metastases (i.e. circulating tumor DNA, ctDNA) represents genetic aberrations in cancer cells, which are a potential source for diagnostic, prognostic, and predictive biomarkers. Recent studies have demonstrated technical feasibility and clinical applications including detection of drug targets and resistance mutations as well as longitudinal monitoring of tumors under therapy. To this end, a variety of pre-analytical procedures for blood processing, isolation and quantification of cfDNA are being employed and several analytical methods and technologies ranging from PCR-based single locus assays to genome-wide approaches are available, which considerably differ in sensitivity, specificity, and throughput. However, broad implementation of ctDNA analysis in daily clinical practice requires a thorough understanding of theoretical, technical, and biological concepts and necessitates standardization and validation of pre-analytical and analytical procedures across different technologies. Here, we review the pertinent literature and discuss the advantages and limitations of available methodologies and their potential applications in molecular diagnostics.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Cell-Free DNA: Applications in Different Diseases.Methods Mol Biol. 2019;1909:3-12. doi: 10.1007/978-1-4939-8973-7_1. Methods Mol Biol. 2019. PMID: 30580419
-
Methods for Measuring ctDNA in Lymphomas.Methods Mol Biol. 2019;1881:253-265. doi: 10.1007/978-1-4939-8876-1_19. Methods Mol Biol. 2019. PMID: 30350211
-
Dynamic Treatment Stratification Using ctDNA.Recent Results Cancer Res. 2020;215:263-273. doi: 10.1007/978-3-030-26439-0_14. Recent Results Cancer Res. 2020. PMID: 31605234 Review.
-
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.Lung Cancer. 2017 May;107:100-107. doi: 10.1016/j.lungcan.2016.04.026. Epub 2016 May 4. Lung Cancer. 2017. PMID: 27180141 Review.
-
Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.Cancer Treat Rev. 2020 Feb;83:101951. doi: 10.1016/j.ctrv.2019.101951. Epub 2019 Dec 13. Cancer Treat Rev. 2020. PMID: 31874446
Cited by
-
Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.PLoS One. 2019 Dec 20;14(12):e0226853. doi: 10.1371/journal.pone.0226853. eCollection 2019. PLoS One. 2019. PMID: 31860648 Free PMC article.
-
Toward the Development of a Circulating Free DNA-Based In Vitro Diagnostic Test for Infectious Diseases: a Review of Evidence for Tuberculosis.J Clin Microbiol. 2019 Mar 28;57(4):e01234-18. doi: 10.1128/JCM.01234-18. Print 2019 Apr. J Clin Microbiol. 2019. PMID: 30404942 Free PMC article. Review.
-
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.Front Oncol. 2020 Apr 3;10:445. doi: 10.3389/fonc.2020.00445. eCollection 2020. Front Oncol. 2020. PMID: 32318342 Free PMC article. Review.
-
S1-Leitlinie: Tumorgenetik – Diagnostik im Kontext maligner Erkrankungen.Med Genet. 2022 May 7;34(1):53-68. doi: 10.1515/medgen-2022-2112. eCollection 2022 Apr. Med Genet. 2022. PMID: 38836013 Free PMC article. German. No abstract available.
-
Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?Cancer Commun (Lond). 2021 Jan;41(1):3-15. doi: 10.1002/cac2.12118. Epub 2020 Dec 2. Cancer Commun (Lond). 2021. PMID: 33264481 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical